Connection

Co-Authors

This is a "connection" page, showing publications co-authored by BANU K ARUN and ABENAA BREWSTER.
Connection Strength

1.120
  1. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.174
  2. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109.
    View in: PubMed
    Score: 0.164
  3. The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes. Oncologist. 2013; 18(5):493-500.
    View in: PubMed
    Score: 0.112
  4. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):276-82.
    View in: PubMed
    Score: 0.101
  5. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
    View in: PubMed
    Score: 0.081
  6. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res. 2007 Aug 15; 13(16):4943-8.
    View in: PubMed
    Score: 0.076
  7. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun. 2024 Oct 01; 4(10):2823-2834.
    View in: PubMed
    Score: 0.062
  8. Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell. 2022; 5:876100.
    View in: PubMed
    Score: 0.053
  9. Influencers of the Decision to Undergo Contralateral Prophylactic Mastectomy among Women with Unilateral Breast Cancer. Cancers (Basel). 2021 Apr 23; 13(9).
    View in: PubMed
    Score: 0.049
  10. Feasibility and efficacy of a weight gain prevention intervention for breast cancer patients receiving neoadjuvant chemotherapy: a randomized controlled pilot study. Support Care Cancer. 2020 Dec; 28(12):5821-5832.
    View in: PubMed
    Score: 0.045
  11. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
    View in: PubMed
    Score: 0.041
  12. Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged = 55 years. Mol Carcinog. 2015 Apr; 54(4):281-90.
    View in: PubMed
    Score: 0.029
  13. Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
    View in: PubMed
    Score: 0.026
  14. Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case-control study. Breast Cancer Res Treat. 2012 Apr; 132(3):1147-55.
    View in: PubMed
    Score: 0.026
  15. The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat. 2010 Jul; 122(1):243-9.
    View in: PubMed
    Score: 0.022
  16. Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009 Jan 10; 27(2):279-88.
    View in: PubMed
    Score: 0.021
  17. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008 Apr 01; 112(7):1455-61.
    View in: PubMed
    Score: 0.020
  18. Building a predictive breast cancer risk model. AMIA Annu Symp Proc. 2007 Oct 11; 995.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.